Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Sarcosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sarcosine SCHEMBL27814416 | 0.95 | CTH (0.39) | GLRA1SLC6A9OR51E2LMNAGABRR1 | |
| Sarcosine SCHEMBL28497446 | 0.90 | FFAR3 (0.38) | GLRA1SLC6A9OR51E2LMNAGABRR1 | |
| Sarcosine SCHEMBL1513461 | 0.90 | ALDH1A1 (0.40) | GLRA1SLC6A9OR51E2LMNAGABRR1 | |
| Sarcosine SCHEMBL272983 | 0.89 | GLRA1 (0.56) | GLRA1SLC6A9OR51E2LMNAGABRR1 | |
| Sarcosine SCHEMBL31427574 | 0.88 | — | — | |
| Sarcosine SCHEMBL149 | 0.88 | — | — | |
| Sarcosine SCHEMBL26641423 | 0.88 | LDHA (0.44) | GLRA1SLC6A9OR51E2LMNAHDAC3 | |
| Sarcosine SCHEMBL28259932 | 0.88 | — | — | |
| Sarcosine SCHEMBL156329 | 0.88 | LDHA (0.44) | GLRA1SLC6A9OR51E2LMNAHDAC3 | |
| Sarcosine SCHEMBL20642060 | 0.87 | LMNA (0.44) | GLRA1SLC6A9OR51E2LMNAGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172422-A1 | Methods of Making Pharmacokinetically Improved Compounds Comprising Functional Residues or Groups and Pharmaceutical Compositions Comprising Said Compounds | SURFACE LOGIX, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| CN-101287468-A | Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds | SURFACE LOGIX INC (US) | 2008-10-15 | — | — | CN | disclosed |
| EP-1848437-A2 | METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | Surface Logix, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006089275-A2 | METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172422-A1 | Methods of Making Pharmacokinetically Improved Compounds Comprising Functional Residues or Groups and Pharmaceutical Compositions Comprising Said Compounds | ABCG2, CYP3A5, CYP3A43 | GLRA1 1765/4885SLC6A9 894/4885OR51E2 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.